Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etentamig + daratumumab + lenalidomide
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral (lenalidomide), Intravenous (daratumumab), Subcutaneous (daratumumab), Unknown (etentamig, Investigational)
01
Overview
Etentamig + daratumumab + lenalidomide is an investigational combination therapy being studied for the treatment of multiple myeloma. **Etentamig** is an investigational drug (modality and mechanism not yet public), **daratumumab** is a monoclonal antibody targeting CD38 with immune-mediated antitumor activity, and **lenalidomide** is an immunomodulatory agent that targets cereblon (CRBN), leading to antineoplastic and immunostimulatory effects. This combination is intended to synergistically enhance anti-myeloma activity and is currently in clinical trials for multiple myeloma, with etentamig in dose escalation phases in combination specifically with daratumumab and lenalidomide[3][5].
- Other names
- etentamig + daratumumab + lenalidomide
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD38 (Cluster of Differentiation 38)CRBN (Cereblon)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on etentamig + daratumumab + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etentamig + daratumumab + lenalidomide.